|
Journal Club Seminars
January 23
Weichung Joe Shih, Ph.D.
UMDNJ
Bridging Clinical Trials - What Are They?
February 13
Weili He, Ph.D.
Merck Co.
A Model-Based Approach in the Estimation of the Maximum Tolerated Dose
in Phase I Cancer Clinical Trials
Febuary 27
Jason Liao, Ph.D.
UMDNJ
Breaking Root N Barrier in Monte Carlo Integration
March 12
Shou-En Lu, Ph.D.
UMDNJ
Case-Cohort Design and Analysis for Clustered Failure Time Data
April 16
Andre Rogatko, Ph.D.
Fox Chase Cancer Center
Patient Specific Dosing in Phase I Clinical Trials: The Role of EWOC
April 24
Gordon Lan, Ph.D.
Aventis Pharmaceuticals
Select the Winner in Drug Development
April 30
Pei-Ling Chu, Ph.D. Student
UMDNJ
Model-Based Designs for Phase I Cancer Clinical Trials
May 14
Pamela Ohman-Strickland, Ph.D.
UMDNJ
Data Reduction using Growth Models in Protein Folding
Prediction - Work in Progress
May 19
Peiling Chu, Ph.D. Cadidate
UMDNJ
Title: Model-Based Designs for Phase I Cancer Clinical Trials
Location:CINJ, Room 5546
Time: 10:00 am on Wednesday, May 19, 2004
May 28
Yong Lin , Ph.D.
UMDNJ
Statistical Properties of Modified Algorithm-Based Designs
for Phase I Cancer Clinical Trials
June 11
Jason Liao , Ph.D.
UMDNJ
Logistic Regression when the number of predictors is larger then the number of subjects: Application to microarray data
September 10
Shou-En Lu , Ph.D.
UMDNJ
Modeling the Association between PM2.5 and Emergency Department Visits in New Jersey
September 24
Susan Huyck, M.S.
Statistician, Schering-Plough Research Institute, and Ph.D. student, UMDNJ
Method Validation in the Pharmaceutical Industry - One Approach
October 8
Dirk Moore, Ph.D.
UMDNJ
Repeated Measures Modeling of the Mouse Hippocampus in Recombinant Inbred Strains
October 22
Yen-Hong Kuo, M.S.
Jersey Shore Medical Center
Issues in Assessing Statistical Associations in Medical Research
November 12
Daniel Zelterman, Ph.D.
Epidemiology and Public Health, Yale University
Statistical Inference in Familial Disease Clusters
December 10
Joanna H. Shih, Ph.D.
Biometric Research Branch, Division of Cancer Treatment and Diagnosis
National Cancer Institute
Estimating Relative Risk, Cumulative Risk and Familial Aggregation From Case-Control Designs With Genotype and Family History Data
|
